JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

about

Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib.

P2860

Q55426864-C3CDF82E-9126-4F68-BBF9-213C7882E7C7

P2860

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Item

http://www.wikidata.org/entity/Q48556502

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

@en

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

@nl

type

Item

label

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

@en

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

@nl

prefLabel

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

@en

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

@nl

P1476

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

@en

P2093

Alejandro Villarino

http://www.w3.org/2001/XMLSchema#string

John J O'Shea

http://www.w3.org/2001/XMLSchema#string

Massimo Gadina

http://www.w3.org/2001/XMLSchema#string

Michael Ward

http://www.w3.org/2001/XMLSchema#string

Yuka Kanno

http://www.w3.org/2001/XMLSchema#string

P2860

Revisiting Crohn's disease as a primary immunodeficiency of macrophages

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

C-reactive protein: a critical update

Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist

Long-term activation of the innate immune system in atherosclerosis

Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

P2888

nrd.2017.267

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD.2017.267

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniella M Schwartz

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29282366

http://www.w3.org/2001/XMLSchema#string

P932

6168198

http://www.w3.org/2001/XMLSchema#string

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

about

P2860

P2860

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932